Cinnarizine + domperidone

Full Prescribing Info
Dosage/Direction for Use

Motion sickness
Adult: Each tab contains cinnarizine 20 mg and domperidone 15 mg: 1 tab taken 1-2 hr before travel and 1 tab every 6 hr during journey if necessary.
Hypersensitivity. Parkinson's disease. GI haemorrhage, obstruction and perforation, patients with prolactin releasing pituitary hormone or chronic admin or for prophylaxis of postoperative nausea and vomiting. Neonates, children.
Special Precautions
Hypotension. May impair ability to drive or operate machinery. Pheochromocytoma; renal or hepatic impairment; risk of cardiac arrhythmias and hypokalaemia if administered IV. Pregnancy, lactation; elderly.
Adverse Reactions
Extrapyramidal symptoms sometimes associated with severe depression. Drowsiness, headache, GI upsets, unsteadiness, headache; rarely skin and hypersensitivity reactions, dry mouth, thickened resp depression, blurred vision, urinary difficulty or retention, constipation and increased gastric reflux, fatigue. Hypolipidaemic effect, extrapyramidal reactions, galactorrhoea, gynaecomastia; lassitude, decreased libido, skin rash, itch.
Potentially Fatal: Convulsions, arrhythmias and cardiac arrest, dysrrhythmias in patients with CVS disease or hypokalaemia, patients on cancer chemotherapy. Seizures, hypertensive crisis in patients with phaeochromocytoma.
Drug Interactions
CNS depressant effect of cinnarizine is enhanced with alcohol. Domperidone reduces absorption of oral digoxin. It increases absorption of aspirin, paracetamol and oral diazepam. Enhances CNS depression by phenothiazine. Antimuscarinic agents and opioids antagonise GI effects. Prolongs suxamethonium-induced neuromuscular blockade.
Food Interaction
Delayed absorption but higher bioavailability due to reduced first-pass metabolism in gut wall.
Cinnarizine has Ca channel blocking activity selective for arterial smooth muscles. It has some antihistamine activity. Cinnarizine acts as a labyrinthine sedative. It also improves microcirculation by reducing ischaemia-induced blood viscosity. Domperidone is a peripheral dopamine-receptor blocker. It increases both the oesophageal peristalsis and the lower oesophageal sphincter pressure. It also increases gastric motility and peristalsis, and enhances gastroduodenal coordination, thus facilitating gastric emptying and decreasing small bowel transit time.
CIMS Class
ATC Classification
A03FA03 - domperidone ; Belongs to the class of propulsives. Used in the treatment of functional gastrointestinal disorders.
N07CA02 - cinnarizine ; Belongs to the class of antivertigo preparations.
Disclaimer: This information is independently developed by CIMS based on cinnarizine + domperidone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in